To assess the associations of semaglutide with incident CUD (first time diagnosis of CUD), the study population included 83,189 patients who had active medical encounters for the diagnosis of obesity in 6/202112/2022, were for the first time (new users design) prescribed semaglutide or non-GLP-1RA anti-obesity medications (bupropion, naltrexone, orlistat, topiramate, phentermine) [39] during 6/2021-12/2022 (time zero or index event), had no diagnosis of CUD on or before the index event and had a diagnosis of at least one of obesity-associated comorbidities (T2D, hypertension, hypercholesterolemia, hyperlipidemia, heart diseases, stroke) on or before the index event
The most commonly reported effects are mild headache, light water retention, mild appetite increase, and tingling in the hands or feet
During this period, he regained most of the weight
A weight-loss plateau is a normal and expected part of the process, even with GLP-1 medications like semaglutide
Depending on your specific situation, your maintenance dose could be lower than 15 mg once a week